Anti-OX40 Antibody in Head and Neck Cancer Patients

Providence Health & Services

Status and phase: Completed; Phase 1

Conditions: Head and Neck Cancer

Treatments: Procedure: Surgical Resection; Drug: Anti-OX40 antibody administration

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02274155

14-042A

Details and patient eligibility

About

The purpose of this study is to test the safety of the anti-OX40 antibody, MEDI6469, given prior to surgery in patients with advanced head and neck squamous cell carcinoma.

Full description

This phase Ib clinical trial uses MEDI6469 at various dose intervals prior to definitive surgical resection of patients with stage III and IV Oral Head and Neck Squamous Cell Carcinoma (OHNSCC) with the primary objective of determining the safety and feasibility of preoperative MEDI6469 administration. In addition, tumor tissue and peripheral blood will be obtained for exploratory immunologic end points including measurements of tumor infiltrating immune cell populations based on flow cytometry and immunohistochemistry as well as circulating immunological parameters that may correlate with changes induced by MEDI6469 administration.

Enrollment: 17 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with treatment naive, resectable, stage III or IV squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx who are candidates for definitive surgical resection followed by standard risk adapted adjuvant therapy.
• Histologic or cytologic diagnosis of a primary OHNSCC with no radiological evidence of metastatic disease is acceptable. Patients with bone or cartilage invasion and any T or N stage are acceptable.
• Patients with oral cavity primaries will be managed using conventional transoral or transcervical techniques; oropharynx or hypopharynx tumor will be managed with transoral robotic surgery; and larynx tumors (T3/T4 with thyroid cartilage invasion) will be managed by either total laryngectomy or larynx preservation surgery.
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
• Laboratory values (performed within 28 days prior to enrollment) within protocol defined range
• Ability to give informed consent and comply with the protocol. Patients with a history of psychiatric illness must be judged able to understand the investigational nature of the study and the risks associated with the therapy.
• No active gastrointestinal bleeding.
• Anticipated lifespan greater than 12 weeks.

Exclusion criteria

• Locoregionally unresectable or Metastatic disease (stage IVB)
• Active infection.
• Active autoimmune disease including patients with Inflammatory Bowel Disease as determined by an autoimmune questionnaire.
• Previous treatment with mouse monoclonal antibodies
• Need for chronic maintenance oral steroids > 5mg prednisone daily equivalent.
• Any medical or psychiatric condition that in the opinion of the investigator would preclude compliance with study procedures.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

17 participants in 3 patient groups

Group 1

Experimental group

Description:

Anti-OX40 antibody administration 3 weeks prior to surgical resection

Treatment:

Drug: Anti-OX40 antibody administration

Procedure: Surgical Resection

Group 2

Experimental group

Description:

Anti-OX40 antibody administration 2 weeks prior to surgical resection

Treatment:

Drug: Anti-OX40 antibody administration

Procedure: Surgical Resection

Group 3

Experimental group

Description:

Anti-OX40 antibody administration 1 week prior to surgical resection

Treatment:

Drug: Anti-OX40 antibody administration

Procedure: Surgical Resection